Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule with the chemical formula C17H13F3N2O2 and a molecular weight of 334.29 g/mol. It is structurally characterized by an indazole core substituted at position 7 with a trifluoromethyl group and at position 3 with a benzene ring bearing two hydroxyl groups (resorcinol moiety), as well as an allyl group at the N^1-position[2][9][10]. This compound has been studied in structural biology for its interaction with estrogen receptors and is referenced as a ligand in crystallographic studies of estrogen receptor-ligand complexes[5]. Its mechanism of action involves binding to the estrogen receptor, likely acting as an agonist or modulator based on its use in ligand selectivity studies[5]. There are no known approved therapeutic indications or marketed products containing this compound; it appears to be used primarily for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol.